Dergi makalesi Açık Erişim

Development of an RP-HPLC method to evaluate the basic characteristics of talazoparib-loaded PLGA nanoparticles

Topcu, Beril Tas; Kaplan, Ozan; Pehlivan, Sibel Bozdag; Celebier, Mustafa; Oner, Levent


DataCite XML

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://aperta.ulakbim.gov.tr/record/278015</identifier>
  <creators>
    <creator>
      <creatorName>Topcu, Beril Tas</creatorName>
      <givenName>Beril Tas</givenName>
      <familyName>Topcu</familyName>
      <affiliation>Hacettepe Univ, Fac Pharm, Dept Pharmaceut Technol, Ankara, Turkiye</affiliation>
    </creator>
    <creator>
      <creatorName>Kaplan, Ozan</creatorName>
      <givenName>Ozan</givenName>
      <familyName>Kaplan</familyName>
      <affiliation>Hacettepe Univ, Fac Pharm, Dept Analyt Chem, Ankara, Turkiye</affiliation>
    </creator>
    <creator>
      <creatorName>Pehlivan, Sibel Bozdag</creatorName>
      <givenName>Sibel Bozdag</givenName>
      <familyName>Pehlivan</familyName>
      <affiliation>Hacettepe Univ, Fac Pharm, Dept Pharmaceut Technol, Ankara, Turkiye</affiliation>
    </creator>
    <creator>
      <creatorName>Celebier, Mustafa</creatorName>
      <givenName>Mustafa</givenName>
      <familyName>Celebier</familyName>
      <affiliation>Hacettepe Univ, Fac Pharm, Dept Analyt Chem, Ankara, Turkiye</affiliation>
    </creator>
    <creator>
      <creatorName>Oner, Levent</creatorName>
      <givenName>Levent</givenName>
      <familyName>Oner</familyName>
      <affiliation>Hacettepe Univ, Fac Pharm, Dept Pharmaceut Technol, Ankara, Turkiye</affiliation>
    </creator>
  </creators>
  <titles>
    <title>Development Of An Rp-Hplc Method To Evaluate The Basic Characteristics Of Talazoparib-Loaded Plga Nanoparticles</title>
  </titles>
  <publisher>Aperta</publisher>
  <publicationYear>2024</publicationYear>
  <dates>
    <date dateType="Issued">2024-01-01</date>
  </dates>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://aperta.ulakbim.gov.tr/record/278015</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.25135/jcm.2310.2937</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="http://www.opendefinition.org/licenses/cc-by">Creative Commons Attribution</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">&lt;p&gt;The use of poly (ADP -ribose) polymerase (PARP) inhibitors for cancer treatment has been reported previously. Talazoparib is a PARP inhibitor, and its solubility problems encouraged us to prepare talazoparib-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles for use in brain cancer models. To determine the encapsulation efficiency and release profile, a reversed -phase high-pressure liquid chromatography (RP-HPLC) method was developed and validated. A Shiseido 5 mu m C18 100 angstrom column (250 x 4.6 mm) was used with a flow rate of 1.0 mL/min. Isocratic elution was performed using an acetonitrile:phosphate buffer (100 mm, pH 6.25) (35:65 v/v) mixture. The injection volume was 5 mu L and UV detection was performed at 227 nm. The method was linear within the range from 0.1 to 12.5 mu g/mL. The encapsulation efficiency and release profile of the prepared formulation were analyzed using the developed RP-HPLC method, and it was found that the encapsulation efficiency was 65.17% +/- 0.50 and the release of the talazoparib was around 40% within 5 h and remained stable for 25 h. The RP-HPLC method developed in the present study can be adapted for further applications to determine talazoparib in its commercial formulations and proposed encapsulated drug delivery systems.&lt;/p&gt;</description>
  </descriptions>
</resource>
0
0
görüntülenme
indirilme
Görüntülenme 0
İndirme 0
Veri hacmi 0 Bytes
Tekil görüntülenme 0
Tekil indirme 0

Alıntı yap